311 related articles for article (PubMed ID: 16203153)
21. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
Hu X; Stebbins CE
Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
[TBL] [Abstract][Full Text] [Related]
22. Computational studies of TGF-βRI (ALK-5) inhibitors: analysis of the binding interactions between ligand-receptor using 2D and 3D techniques.
Araujo SC; Maltarollo VG; Honorio KM
Eur J Pharm Sci; 2013 Jul; 49(4):542-9. PubMed ID: 23727056
[TBL] [Abstract][Full Text] [Related]
23. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
Honorio KM; Garratt RC; Andricopulo AD
Bioorg Med Chem Lett; 2005 Jun; 15(12):3119-25. PubMed ID: 15893927
[TBL] [Abstract][Full Text] [Related]
24. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
[TBL] [Abstract][Full Text] [Related]
25. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
26. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
27. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
28. 2D- and 3D-QSAR studies on 54 anti-tumor Rubiaceae-type cyclopeptides.
Yan H; Pan X; Tan N; Fan J; Zeng G; Han H
Eur J Med Chem; 2009 Sep; 44(9):3425-32. PubMed ID: 19303172
[TBL] [Abstract][Full Text] [Related]
29. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.
Kuo CL; Assefa H; Kamath S; Brzozowski Z; Slawinski J; Saczewski F; Buolamwini JK; Neamati N
J Med Chem; 2004 Jan; 47(2):385-99. PubMed ID: 14711310
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses.
Liu G; Zhang Z; Luo X; Shen J; Liu H; Shen X; Chen K; Jiang H
Bioorg Med Chem; 2004 Aug; 12(15):4147-57. PubMed ID: 15246091
[TBL] [Abstract][Full Text] [Related]
31. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
[TBL] [Abstract][Full Text] [Related]
32. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents.
Saqib U; Siddiqi MI
SAR QSAR Environ Res; 2009 Jul; 20(5-6):519-35. PubMed ID: 19916112
[TBL] [Abstract][Full Text] [Related]
33. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Sun J; Cai S; Mei H; Li J; Yan N; Wang Q; Lin Z; Huo D
Chem Biol Drug Des; 2010 Sep; 76(3):245-54. PubMed ID: 20626407
[TBL] [Abstract][Full Text] [Related]
34. Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.
Cheng Y; Zhou M; Tung CH; Ji M; Zhang F
Bioorg Med Chem Lett; 2010 Jun; 20(11):3329-37. PubMed ID: 20452766
[TBL] [Abstract][Full Text] [Related]
35. Calf spleen purine-nucleoside phosphorylase: crystal structure of the binary complex with a potent multisubstrate analogue inhibitor.
Luić M; Koellner G; Yokomatsu T; Shibuya S; Bzowska A
Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1417-24. PubMed ID: 15272165
[TBL] [Abstract][Full Text] [Related]
36. Comparative molecular field analysis and comparative molecular similarity indices analysis of boron-containing human thymidine kinase 1 substrates.
Bandyopadhyaya AK; Tiwari R; Tjarks W
Bioorg Med Chem; 2006 Oct; 14(20):6924-32. PubMed ID: 16828556
[TBL] [Abstract][Full Text] [Related]
37. Novel multisubstrate inhibitors of mammalian purine nucleoside phosphorylase.
Toms AV; Wang W; Li Y; Ganem B; Ealick SE
Acta Crystallogr D Biol Crystallogr; 2005 Nov; 61(Pt 11):1449-58. PubMed ID: 16239721
[TBL] [Abstract][Full Text] [Related]
38. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
39. 3D-QSAR and molecular docking studies of 1,3,5-triazene-2,4-diamine derivatives against r-RNA: novel bacterial translation inhibitors.
Sekhar YN; Nayana MR; Sivakumari N; Ravikumar M; Mahmood SK
J Mol Graph Model; 2008 Jun; 26(8):1338-52. PubMed ID: 18372201
[TBL] [Abstract][Full Text] [Related]
40. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
Lee JH; Kang NS; Yoo SE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
